According to 2016 WHO classification of glioma, GBMs are divided into: 1) IDH-wildtype (about 90% of cases), 2) IDH-mutant (about 10% of cases), and 3) IDH not otherwise specified (1). Here, IDH1 is linked to central nervous system cancer.